World first: focused ultrasound opens blood-brain barrier for delivery of therapeutic in Parkinson’s disease
Excerpt from the Article:
In a groundbreaking, world-first clinical trial, a team of researchers from Sunnybrook Health Sciences Centre and University Health Network are using focused ultrasound technology to deliver a therapeutic directly to affected brain regions in patients with Parkinson’s disease (PD).
Parkinson’s affects more than 6 million people around the world. It is a brain disorder that causes tremor, rigidity, slow movement and numerous other disabling symptoms. PD is a progressive neurodegenerative disease currently without a cure, which dramatically impacts a patient’s quality of life. Each patient’s symptoms can progress at a different rate.
Click the button below to continue reading the Article:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?